Indeed, the pharmacological inhibition of both pathways has led to a complete prostate tumor regression in a Pten‐deficient murine prostate cancer model and in human prostate cancer xenografts (Carver et al, 2011). The gene discussed is PTEN; the disease is prostate carcinoma.